![]() ![]() Inhibiting integrase from performing this essential function limits the ability of the virus to replicate and infect new cells. ISENTRESS works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme and has demonstrated rapid antiviral activity. ISENTRESS is the first medicine to be approved in a class of antiretroviral drugs called integrase inhibitors. For Information about this program and others, please visit About ISENTRESS ![]() The SUPPORT Program is a two-part program that consists of free reimbursement support services and a patient assistance program for eligible individuals through a single toll-free call to 1-80. The SUPPORT™ Program is designed to help patients who have been prescribed ISENTRESS or CRIXIVAN® (indinavir sulfate). The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The safety and efficacy of ISENTRESS have not been established in pediatric patients. Two of these studies were conducted in clinically advanced, three-class antiretroviral (ARV) treatment-experienced adults and one was conducted in treatment-naïve adults. The label for ISENTRESS is based on analyses of plasma HIV-1 RNA levels through 96 weeks in three double-blind controlled clinical studies of ISENTRESS. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Participants must be residents of the United States or the Commonwealth of Puerto Rico to be eligible for the program.Įligible patients can enroll in the Savings Coupon program and receive additional information about co-pay assistance by calling 1-87 or at The Savings Coupon for ISENTRESS expires Sept. The program is not available to patients who are covered under Medicaid, Medicare, a Medicare Part D or Medicare Advantage plan (regardless of whether a specific prescription is covered), TRICARE, CHAMPUS, Government Health Insurance Plan (“Healthcare Reform”), or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program, or to residents of Massachusetts. “Given today’s economic climate, programs that help alleviate the high co-pay costs that many HIV-1 patients face are increasingly important" “This effort, along with Merck’s ongoing collaboration with AIDS Drug Assistance Programs (ADAPs), further reinforces the Company’s long-standing commitment to providing access to our medicines,” said Patrick Bergstedt, senior vice president and general manager, Merck Infectious Diseases Franchise. Savings are limited to co-pay amount and eligibility restrictions, terms and conditions apply. The program applies to eligible patients who have private health insurance with a co-payment for the prescription. People who have been prescribed ISENTRESS who meet certain requirements are eligible to participate in the program, in which they can receive a Savings Coupon for up to $400 toward out-of-pocket costs on each of up to 12 eligible prescriptions of ISENTRESS, regardless of the number of tablets supplied on the prescription. The program provides important savings for privately-insured patients with out-of-pocket costs for ISENTRESS, and is part of Merck’s ongoing commitment to providing access to treatment. WHITEHOUSE STATION, N.J., –- Merck today announced an enhanced co-pay assistance program for people living with HIV-1 who are taking the Company’s first-in-class HIV-1 integrase inhibitor, ISENTRESS® (raltegravir) Tablets. Enhanced Program Provides Assistance to People Living with HIV-1 Who are Privately Insured and Have Out-of-Pocket Co-Pays
0 Comments
Leave a Reply. |